The target audience for this Symposium is preclinical and clinical pharmacologists, regulatory and pharmaceutical employees and general medical practitioners.
Description:
There are currently two opposing trends in the development of highly-effective treatments for obesity: First, mechanism-based, “precision” approaches have been developed for some individuals with established molecular etiologies for their obesity. Precision medicine for obesity has become possible for children with defects in the proximal leptin signaling pathway, including leptin deficiency, leptin receptor deficiency, POMC deficiency, PCSK1 deficiency and those with the Bardet-Biedl syndrome. Second, an increasing understanding of the physiological systems that impact food intake has been applied to identify key regulatory nodes that can be pharmacologically affected and have broad efficacy in those without known specific defects, leading to the development of dual- and even triple-agonist drugs for obesity. This session will discuss the current state of pharmacotherapy for pediatric obesity from both perspectives and present some future directions for pediatric obesity pharmacotherapy.
Goals & Objectives:
Following the completion of this activity, the learner will be able to:
Describe use of melanocortin receptor agonists for monogenic pediatric obesities affecting the proximal leptin signaling pathway;
Explain off-label leptin for children with leptin deficiency obesity;
Analyze the efficacy of nonspecific pediatric obesity pharmacology.
